|
1
|
Truelsen T, Heuschmann PU, Bonita R, et
al: Standard method for developing stroke registers in low-income
and middle income countries: experiences from a feasibility study
of a stepwise approach to stroke surveillance (STEPS Stroke).
Lancet Neurol. 6:134–139. 2007. View Article : Google Scholar
|
|
2
|
Saenger AK and Christenson RH: Stroke
biomarkers: progress and challenges for diagnosis, prognosis,
differentiation and treatment. Clin Chem. 56:21–33. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Al Haj Zen A, Caligiuri G, Sainz J, et al:
Decorin overexpression reduces atherosclerosis development in
apolipoprotein E-deficient mice. Atherosclerosis. 187:31–39.
2006.PubMed/NCBI
|
|
4
|
Chen S and Birk DE: Focus on molecules:
decorin. Exp Eye Res. 92:444–445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu Y, Sun H, Owens RT, et al: Decorin
suppresses prostate tumor growth through inhibition of epidermal
growth factor and androgen receptor pathways. Neoplasia.
11:1042–1053. 2009.PubMed/NCBI
|
|
6
|
Johnson PY, Potter-Perigo S, Gooden MD, et
al: Decorin synthesized by arterial smooth muscle cells is retained
in fibrin gels and modulates fibrin contraction. J Cell Biochem.
101:281–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldoni S, Humphries A, Nyström A, et al:
Decorin is a novel antagonistic ligand of the Met receptor. J Cell
Biol. 185:743–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reed CC, Waterhouse A, Kirby S, et al:
Decorin prevents metastatic spreading of breast cancer. Oncogene.
24:1104–1110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iozzo RV, Moscatello DK, McQuillan DJ and
Eichstetter I: Decorin is a biological ligand for the epidermal
growth factor receptor. J Biol Chem. 274:4489–4492. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schönherr E, Sunderkotter C, Iozzo RV and
Schaefer L: Decorin, a novel player in the insulin-like growth
factor system. J Biol Chem. 280:15767–15772. 2005.PubMed/NCBI
|
|
11
|
Kresse H and Schönherr E: Proteoglycans of
the extracellular matrix and growth control. J Cell Physiol.
189:266–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Merle B, Durussel L, Delmas PD and
Clezardin P: Decorin inhibits cell migration through a process
requiring its glycosaminoglycan side chain. J Cell Biochem.
75:538–546. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Yu H, Sun K, et al: Promoter
variant of angiopoietin-2 and plasma angiopoietin-2 are associated
with risk of stroke recurrence in lacunar infarct patients. Biochem
Biophys Res Commun. 398:212–216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adams HP Jr, Bendixen BH, Kappelle LJ, et
al: Classification of subtype of acute ischemic stroke. Definitions
for use in a multicenter clinical trial TOAST Trial of Org 10172 in
Acute Stroke Treatment. Stroke. 24:35–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brott T, Adams HP Jr, Olinger CP, et al:
Measurements of acute cerebral infarction: a clinical examination
scale. Stroke. 20:864–870. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan W, Wang P, Zhao CX, et al: Decorin
gene delivery inhibits cardiac fibrosis in spontaneously
hypertensive rats by modulation of transforming growth
factor-β/Smad and p38 mitogen-activated protein kinase signaling
pathways. Hum Gene Ther. 20:1190–1200. 2009.PubMed/NCBI
|
|
17
|
Zhang Z, Garron TM, Li XJ, et al:
Recombinant human decorin inhibits TGF-β1-induced contraction of
collagen lattice by hypertrophic scar fibroblasts. Burns.
35:527–537. 2009.
|
|
18
|
Zheng F, Lu W, Wu F, et al: Recombinant
decorin ameliorates the pulmonary structure alterations by
down-regulating transforming growth factor-β1/SMADS signaling in
the diabetic rats. Endocr Res. 35:35–49. 2010.PubMed/NCBI
|
|
19
|
Sanches JC, Jones CJ, Aplin JD, et al:
Collagen fibril organization in the pregnant endometrium of
decorin-deficient mice. J Anat. 216:144–155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schaefer L and Iozzo RV: Biological
functions of the small leucine-rich proteoglycans: from genetics to
signal transduction. J Biol Chem. 283:21305–21309. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Murphy G: Matrix metalloproteinases and
their inhibitors. Acta Orthop Scand Suppl. 266:55–60.
1995.PubMed/NCBI
|
|
22
|
de Nooijer R, Verkleij CJ, von der Thüsen
JH, et al: Lesional overexpression of matrix metallopmteinase-9
promotes intraplaque hemorrhage in advanced lesions but not at
earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol.
26:340–346. 2006.PubMed/NCBI
|
|
23
|
Bäck M, Ketelhuth DF and Agewall S: Matrix
metalloproteinases in atherothrombosis. Prog Cardiovasc Dis.
52:410–428. 2010.
|
|
24
|
Horstmann S, Kalb P, Koziol J, et al:
Profiles of matrix metalloproteinases, their inhibitors and laminin
in stroke patients: influence of different therapies. Stroke.
34:2165–2170. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vukasovic I, Tesija-Kuna A, Topic E, et
al: Matrix metalloproteinases and their inhibitors in different
acute stroke subtypes. Clin Chem Lab Med. 44:428–434. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horstmann S, Su Y, Koziol J, et al: MMP-2
and MMP-9 levels in peripheral blood after subarachnoid hemorrhage.
J Neurol Sci. 251:82–6. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dong FQ, Li H, Wu F, et al: Effects of
overexpression of decorin on matrix metalloproteinases 2 and 9 in
rat mesangial and tubular cells. Zhonghua Yi Xue Za Zhi.
88:3444–3447. 2008.(In Chinese).
|
|
28
|
Al Haj Zen A, Lafont A, Durand E, et al:
Effect of adenovirus-mediated overexpression of decorin on
metalloproteinases, tissue inhibitors of metalloproteinases and
cytokines secretion by human gingival fibroblasts. Matrix Biol.
22:251–258. 2003.PubMed/NCBI
|
|
29
|
Ross R: Atherosclerosis is an inflammatory
disease. Am Heart J. 138:419–420. 1999. View Article : Google Scholar
|
|
30
|
Nilupul Perera M, Ma HK, Arakawa S, et al:
Inflammation following stroke. J Clin Neurosci. 13:1–8.
2006.PubMed/NCBI
|
|
31
|
Elkind MS: Inflammatory mechanisms of
stroke. Stroke. 41(Suppl 10): S3–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tuttolomondo A, Di Sciacca R, Di Raimondo
D, et al: Inflammation as a therapeutic target in acute ischemic
stroke treatment. Curr Top Med Chem. 9:1240–1260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tuttolomondo A, Di Raimondo D, Di Sciacca
R, et al: Fetuin-A and CD40 L plasma levels in acute ischemic
stroke: Differences in relation to TOAST subtype and correlation
with clinical and laboratory variables. Atherosclerosis.
208:290–296. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kiewert C, Mdzinarishvili A, Hartmann J,
et al: Metabolic and transmitter changes in core and penumbra after
middle cerebral artery occlusion in mice. Brain Res. 1312:101–107.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang J, Upadhyay UM and Tamargo RJ:
Inflammation in stroke and focal cerebral ischemia. Surg Neurol.
66:232–245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamaguchi Y, Mann DM and Ruoslahti E:
Negative regulation of transforming growth factor-β by the
proteoglycan decorin. Nature. 346:281–4. 1990.
|
